IMC announces "Commitment to Compliance" initiative in response to FDA's "Bad Ad Program"

Informed Medical Communications (IMC), a leading full-service provider of peer-to-peer medical forums and integrated medical communications for the bio-pharmaceutical industry, today announced its "Commitment to Compliance" initiative, responding to the FDA's new program to minimize misleading drug advertising and promotion.  Recognizing the level of complexity the FDA's "Bad Ad Program" adds to pharmaceutical marketing, IMC issued a series of industry communications to reinforce its position on compliant dissemination of pharmaceutical product information.  Additionally, IMC began a multi-faceted campaign to inform the industry regarding its longstanding compliance training policy for its elite team of Medical Moderators and other staff responsible for communications with healthcare professionals.

Steve Budd, IMC's CEO commented, "We're finding that with growing levels of compliance uncertainty in the market, our clients, now more than ever, are valuing the unique role and rigorous training of our Medical Moderators.  I believe our 25 years without compliance violations is a testament to the strong role our Moderators play in ensuring compliance during peer-to-peer events."  With growing challenges facing pharmaceutical marketers, IMC hopes the initiative will provide pharmaceutical customers with added comfort regarding IMC's low-risk, high-impact services for meeting brand objectives.  As Jaime Nguyen, MD, IMC's Compliance Officer summarizes, "IMC's Moderated format for driving deep peer discussion mitigates risk for our clients and enables physicians to engage in germane dialogue on information and data that is on-label, current, and truthful."